GLP-1 Drug Cost by State

Why GLP-1 Coverage Varies by State

GLP-1 medication coverage varies dramatically across the United States because Medicaid programs are administered jointly by federal and state governments, giving each state significant discretion over which drugs to cover and under what conditions. While federal Medicaid law requires coverage of most FDA-approved medications for qualifying diagnoses, obesity treatment — including weight-loss drugs like Wegovy and Zepbound — has long been excluded from federal minimum coverage requirements under the anti-obesity medication exclusion in the Social Security Act.

For diabetes treatment, the picture is clearer: Ozempic (semaglutide) and Mounjaro (tirzepatide), prescribed as diabetes medications, are covered by most Medicaid programs because diabetes is a qualifying diagnosis under federal requirements. But the same molecules — Wegovy and Zepbound — prescribed specifically for weight loss face a patchwork of state decisions. Some states have chosen to cover them voluntarily, others have covered them for a period and then reversed course, and most have never covered them for obesity treatment at all.

Commercial insurance coverage follows a similar pattern. Employer-sponsored plans are governed by ERISA and can exclude any drug class they choose. ACA marketplace plans must cover preventive services but are not required to cover obesity drugs. This means your coverage depends heavily on where you live, who your employer is, and which specific health plan you have selected.

States with the Best Medicaid GLP-1 Coverage

As of 2026, roughly 26 states have some form of Medicaid coverage for GLP-1 medications, though coverage terms vary significantly. The states with the most comprehensive Medicaid GLP-1 coverage include:

• Illinois: Covers Wegovy and Zepbound for obesity treatment with prior authorization and BMI requirement of 30+ (or 27+ with comorbidity).
• New York: Medicaid covers GLP-1s for both diabetes and obesity, with relatively straightforward prior authorization.
• Washington: Apple Health (Medicaid) covers anti-obesity medications including GLP-1s for qualifying enrollees.
• Colorado: Covers GLP-1 medications for obesity treatment with step therapy requirements.
• Massachusetts: MassHealth covers GLP-1s with prior authorization for BMI thresholds.

Even in states with coverage, patients often face prior authorization requirements, step therapy (requiring documented failure of other weight-loss interventions first), and quantity limits. Coverage can also change — states can add or remove drugs from their Medicaid formulary each year.

States That Recently Changed GLP-1 Coverage

GLP-1 coverage has been in flux as state budgets feel the impact of high-cost medications. The most significant recent change:

California (Medi-Cal) — Coverage Ended January 2026: California had been one of the more generous states, covering Wegovy and other anti-obesity GLP-1 medications through Medi-Cal. However, facing significant budget pressures — GLP-1 drugs were costing the program hundreds of millions of dollars annually — California ended coverage for GLP-1 medications prescribed solely for weight loss effective January 1, 2026. Medi-Cal continues to cover Ozempic and Mounjaro when prescribed for Type 2 diabetes. Patients who were previously covered for weight-loss indications needed to transition to other treatment options or find alternative funding.

Texas: Texas Medicaid has not historically covered anti-obesity medications, and that position has not changed. However, Texas has expanded coverage of GLP-1s for diabetes management in recent years.

Federal Medicare Changes: The Inflation Reduction Act created a pathway for Medicare to negotiate drug prices, and GLP-1 medications are expected to be among the drugs subject to negotiation in future cycles. Additionally, there have been ongoing legislative proposals to require Medicare Part D to cover anti-obesity medications — as of 2026 this has not passed, so Medicare still does not cover Wegovy or Zepbound for weight loss, though it covers Ozempic and Mounjaro for diabetes.

How to Check Your State's GLP-1 Coverage

The most reliable way to verify current GLP-1 coverage in your state is to look directly at your plan's formulary — the official list of covered medications. Here's how:

1. For Medicaid: Visit your state's Medicaid website and search for the current preferred drug list (PDL) or formulary. Look for semaglutide, tirzepatide, or the brand names Ozempic, Wegovy, Mounjaro, Zepbound. Note whether coverage is for diabetes (ICD-10 code E11.x) or obesity (ICD-10 code E66.x) — many states cover one but not the other.
2. For Medicare Part D: Use Medicare's Plan Finder tool at medicare.gov to see if your specific Part D plan covers the medication you're prescribed. Coverage varies by plan even within Medicare.
3. For Commercial Insurance: Log into your insurer's member portal and use the drug cost estimator tool. Enter the exact drug name and dosage. Call member services if the formulary lookup is unclear — ask specifically whether prior authorization is required and what the step therapy requirements are.
4. Ask Your Doctor's Office: Most specialty and endocrinology practices have prior authorization coordinators who know which insurers routinely approve GLP-1s. They can tell you upfront what your chances of approval are and what documentation you'll need.

HSA and FSA Eligibility for GLP-1 Medications

If you're paying out of pocket for GLP-1 medications, Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) can significantly reduce your after-tax cost. Since GLP-1 medications are FDA-approved prescription drugs, they qualify as eligible medical expenses under IRS rules — meaning you can pay for them with pre-tax HSA or FSA funds regardless of whether you're using them for diabetes or weight loss.

The tax benefit is meaningful: if you're in the 22% federal tax bracket and pay $400/month for compounded semaglutide or a manufacturer program, using HSA funds saves you roughly $88/month in federal taxes. State income tax treatment of HSA contributions varies — most states conform to federal treatment, but California and New Jersey do not offer a state tax deduction for HSA contributions. FSA funds must generally be used within the plan year, making them better suited for predictable GLP-1 costs than one-time purchases.

Frequently Asked Questions